Drug intelligence / Profile preview

haloperidol + ketamine

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of haloperidol, a high-potency first-generation antipsychotic, and ketamine, an NMDA receptor antagonist with dissociative anesthetic properties. This combination is used for managing acute agitation, delirium, and pain in emergency settings. Haloperidol works primarily through dopamine D2 receptor antagonism, while ketamine blocks NMDA receptors. The combination provides rapid sedation with complementary effects - haloperidol can reduce some cognitive impairments produced by ketamine while maintaining effective sedation.

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on haloperidol + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + ketamine.

Explore the full profile